The US Food and Drug Administration (USFDA) has conducted a Pre-Approval Inspection (PAI) for Doxorubicin Liposomal, a complex oncological injectable at Alidac Pharmaceuticals, the injectable onco manufacturing facility, located at Pharmez, Ahmedabad from March 18 to 26, 2019. The inspection concluded with one observation.
Alidac Pharmaceuticals is a 100% subsidiary of Cadila Healthcare. The company is addressing these observations and is confident of getting the product approval at the earliest.
Cadila Healthcare is an India-based pharmaceutical company. The company’s subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.
